The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The glob­al pan­dem­ic may have roiled economies, killed hun­dreds of thou­sands and throt­tled en­tire in­dus­tries, but the on­ly ef­fect it had on bio­phar­ma ven­ture in­vest­ing was to help tur­bocharge the field to gid­dy new heights.

Be­low you’ll find the new top 100 ven­ture in­vestors in the in­dus­try, ranked by the num­ber of deals they were pub­licly in­volved in, as tracked by Deal­For­ma chief Chris Doko­ma­ji­lar. The num­bers mas­ter then cal­cu­lat­ed the es­ti­mat­ed amount of mon­ey they put in­to each deal — divvy­ing up the cash by the num­ber of play­ers — to in­di­cate how they man­aged their syn­di­cates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA